Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Borazan, A. Karalezli, Y. Akova, A. Akman, H. Kıyıcı, S. Erbek (2009)
Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo‐controlled environmental trialActa Ophthalmologica, 87
H. King (1992)
Mast cell stabilizersOtolaryngology—Head and Neck Surgery, 107
Karl‐Friedrich Deml, S. Beermann, D. Neumann, A. Strasser, R. Seifert (2009)
Interactions of Histamine H1-Receptor Agonists and Antagonists with the Human Histamine H4-ReceptorMolecular Pharmacology, 76
Shilpi Pradhan, K. Abhishek, F. Mah (2009)
Epinastine: topical ophthalmic second generation antihistamine without significant systemic side effectsExpert Opinion on Drug Metabolism & Toxicology, 5
C. Smuda, P. Bryce (2011)
New Developments in the Use of Histamine and Histamine ReceptorsCurrent Allergy and Asthma Reports, 11
I. Finegold, D. Granet, P. D'Arienzo, A. Epstein (2006)
Efficacy and response with olopatadine versus epinastine in ocular allergic symptoms: a post hoc analysis of data from a conjunctival allergen challenge study.Clinical therapeutics, 28 10
O. Kari, O. Salo, L. Halmepuro, K. Suvilehto (2005)
Tear histamine during allergic conjunctivitis challengeGraefe's Archive for Clinical and Experimental Ophthalmology, 223
Y. Nakano, Yuji Takahashi, Rie Ono, Yasunori Kurata, Yoto Kagawa, C. Kamei (2009)
Role of histamine H(4) receptor in allergic conjunctivitis in mice.European journal of pharmacology, 608 1-3
M. Strakhova, C. Cuff, A. Manelli, T. Carr, D. Witte, JL Baranowski, TA Vortherms, T. Miller, L. Rundell, M. McPherson, RM Adair, AA Brito, BM Bettencourt, B. Yao, J. Wetter, K. Marsh, H. Liu, M. Cowart, J. Brioni, T. Esbenshade (2009)
In vitro and in vivo characterization of A‐940894: a potent histamine H4 receptor antagonist with anti‐inflammatory propertiesBritish Journal of Pharmacology, 157
M. Abelson (2004)
A review of olopatadine for the treatment of ocular allergyExpert Opinion on Pharmacotherapy, 5
G. Torkildsen, A. Shedden (2011)
Original article The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis
A. Avunduk, M. Avunduk, Z. Kapıcıoǧlu, N. Akyol, Lema Tavli (2000)
Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis.Ophthalmology, 107 7
M. Leite-de-Moraes, Séverine Diem, Marie‐Laure Michel, H. Ohtsu, R. Thurmond, E. Schneider, M. Dy (2009)
Cutting Edge: Histamine Receptor H4 Activation Positively Regulates In Vivo IL-4 and IFN-γ Production by Invariant NKT Cells1The Journal of Immunology, 182
M. Abelson, I. Udell (1981)
H2-receptors in the human ocular surface.Archives of ophthalmology, 99 2
M. Abelson, P. Gomes (2008)
Olopatadine 0.2% ophthalmic solution: the first ophthalmic antiallergy agent with once-daily dosing.Expert opinion on drug metabolism & toxicology, 4 4
M. Abelson, D. Spangler, A. Epstein, F. Mah, H. Crampton (2007)
Efficacy of Once-Daily Olopatadine 0.2% Ophthalmic Solution Compared to Twice-Daily Olopatadine 0.1% Ophthalmic Solution for the Treatment of Ocular Itching Induced by Conjunctival Allergen ChallengeCurrent Eye Research, 32
W. Parys, S. Blockhuys, M. Janssens (2004)
New trends in the treatment of allergic conjunctivitisDocumenta Ophthalmologica, 82
B. Savall, J. Edwards, Jennifer Venable, D. Buzard, R. Thurmond, M. Hack, Patricia McGovern (2010)
Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.Bioorganic & medicinal chemistry letters, 20 11
M. Sanchis-Merino, J. Montero, J. Ruiz-Moreno, Alejandra Rodríguez, S. Pastor (2008)
Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis.Experimental eye research, 86 5
A. Secchi, G. Ciprandi, A. Leonardi, J. Deschênes, M. Abelson (2000)
Safety and Efficacy Comparison of Emedastine 0.05% Ophthalmic Solution Compared to Levocabastine 0.05% Ophthalmic Suspension in Pediatric Subjects with Allergic ConjunctivitisActa Ophthalmologica Scandinavica, 78
Junping Li, R. Tripathi, B. Tripathi (2008)
Drug-Induced Ocular DisordersDrug Safety, 31
A. Secchi, G. Ciprandi, A. Leonardi, J. Deschênes, M. Abelson (2000)
Safety and efficacy comparison of emedastine 0.05% ophthalmic solution compared to levocabastine 0.05% ophthalmic suspension in pediatric subjects with allergic conjunctivitis. Emadine Study Group.Acta ophthalmologica Scandinavica. Supplement, 230
S. Cramp, H. Dyke, C. Higgs, D. Clark, M. Gill, P. Savy, N. Jennings, Steve Price, P. Lockey, D. Norman, Soraya Porres, F. Wilson, Alison Jones, N. Ramsden, R. Mangano, Dan Leggate, M. Andersson, R. Hale (2010)
Identification and hit-to-lead exploration of a novel series of histamine H4 receptor inverse agonists.Bioorganic & medicinal chemistry letters, 20 8
Francis Mah, Terrence O'Brien, Terry Kim, G. Torkildsen (2008)
Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye*Current Medical Research and Opinion, 24
A. Leonardi, L. Quintieri (2010)
Olopatadine: a drug for allergic conjunctivitis targeting the mast cellExpert Opinion on Pharmacotherapy, 11
J. Cowden, Jason Riley, J. Ma, R. Thurmond, P. Dunford (2010)
Histamine H4 receptor antagonism diminishes existing airway inflammation and dysfunction via modulation of Th2 cytokinesRespiratory Research, 11
M. Abelson, W. Chambers, Lisa Smith (1990)
Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis.Archives of ophthalmology, 108 1
S. Butrus, R. Portela (2005)
Ocular allergy: diagnosis and treatment.Ophthalmology clinics of North America, 18 4
J. Greiner, C. Michaelson, C. McWhirter, Naveed Shams (2002)
Single dose of ketotifen fumarate .025% vs 2 weeks of cromolyn sodium 4% for allergic conjunctivitisAdvances in Therapy, 19
R. Dockhorn, T. Duckett (1994)
Comparison of Naphcon-A and its components (naphazoline and pheniramine) in a provocative model of allergic conjunctivitis.Current eye research, 13 5
L. Rosenwasser, T. Mahr, M. Abelson, P. Gomes, Kathryn Kennedy (2008)
A comparison of olopatadine 0.2% ophthalmic solution versus fluticasone furoate nasal spray for the treatment of allergic conjunctivitis.Allergy and asthma proceedings, 29 6
Saurbhi Khurana, N. Sharma, T. Agarwal, B. Chawla, T. Velpandian, R. Tandon, J. Titiyal (2010)
Comparison of Olopatadine and Fluorometholone in Contact Lens-Induced Papillary ConjunctivitisEye & Contact Lens: Science & Clinical Practice, 36
R. Kiss, György Keseru˝ (2009)
Histamine H4 receptor ligands and their potential therapeutic applicationsExpert Opinion on Therapeutic Patents, 19
A. Qasem, C. Bucolo, M. Baiula, A. Spartà, P. Govoni, A. Bedini, D. Fascì, S. Spampinato (2008)
Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine.Biochemical pharmacology, 76 6
H. Bohets, C. McGowan, G. Mannens, N. Schroeder, Kimberly Edwards-Swanson, A. Shapiro (2011)
Clinical pharmacology of alcaftadine, a novel antihistamine for the prevention of allergic conjunctivitis.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 27 2
G. Ciprandi, S. Buscaglia, P. Cerqueti, G. Canonica (1992)
Drug treatment of allergic conjunctivitis. A review of the evidence.Drugs, 43 2
G. Hsieh, P. Chandran, A. Salyers, M. Pai, Chang Zhu, E. Wensink, D. Witte, T. Miller, J. Mikusa, S. Baker, Jill Wetter, K. Marsh, A. Hancock, M. Cowart, T. Esbenshade, J. Brioni, P. Honore (2010)
H4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in ratsPharmacology Biochemistry and Behavior, 95
M. Abelson, Michelle George, Kendyl Schaefer, Lisa Smith (1994)
Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis.The Journal of allergy and clinical immunology, 94 3 Pt 1
Úrsula Giedion, Yadira Diaz (2009)
A review of the evidence
J. Yanni, Steven Miller, D. Gamache, J. Spellman, Shou Xu, Najam Sharif (1997)
Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 79 6
Chinnadurai Saravanan, S. Bharti, S. Jaggi, Sushil Singh (2011)
Histamine H₄ receptor: a novel target for inflammation therapy.Mini reviews in medicinal chemistry, 11 2
G. Torkildsen, M. Abelson, P. Gomes (2008)
Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis.Clinical therapeutics, 30 7
M. Abelson, A. Paradis, M. George, L. Smith, L. Maguire, R. Burns (1990)
Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis.Archives of ophthalmology, 108 4
M. Abelson, Darell Turner (2003)
A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.Clinical therapeutics, 25 3
G. Fahy, D. Easty, L. Collum, A. Benedict-Smith, M. Hillery, D. Parsons (1992)
Randomised Double-Masked Trial of Lodoxamide and Sodium Cromoglycate in Allergic Eye DiseaseEuropean Journal of Ophthalmology, 2
M. Abelson, Lisa Smith, M. Chapin (2003)
Ocular allergic disease: mechanisms, disease sub-types, treatment.The ocular surface, 1 3
M. Abelson, G. Berdy, T. Mundorf, L. Amdahl, A. Graves (2002)
Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 18 5
M. Abelson, K. Schaefer (1993)
Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy.Survey of ophthalmology, 38 Suppl
A. Epstein, Peter Hoven, A. Kaufman, W. Carr (2009)
Management of allergic conjunctivitis: an evaluation of the perceived comfort and therapeutic efficacy of olopatadine 0.2% and azelastine 0.05% from two prospective studiesClinical ophthalmology (Auckland, N.Z.), 3
G. Galatowicz, Yetunde Ajayi, M. Stern, V. Calder (2007)
Ocular anti‐allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivoClinical & Experimental Allergy, 37
C. Akdis, K. Blaser (2003)
Histamine in the immune regulation of allergic inflammation.The Journal of allergy and clinical immunology, 112 1
Patricia Williams, Elizabeth Crandall, J. Sheppard (2010)
Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitisClinical Ophthalmology (Auckland, N.Z.), 4
A. Avunduk, Y. Tekelioğlu, Adem Turk, N. Akyol (2005)
Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.Clinical therapeutics, 27 9
M. Abelson, Andrea Leonardi, Lisa Smith, I. Fregona, Michelle George, A. Secchi (1995)
Histaminase activity in patients with vernal keratoconjunctivitis.Ophthalmology, 102 12
G. Ciprandi, S. Buscaglia, P. Cerqueti, G. Canonica (1992)
Drug Treatment of Allergic ConjunctivitisDrugs, 43
A. Secchi, A. Leonardi, M. Discepola, J. Deschênes, M. Abelson (2000)
An Efficacy and Tolerance Comparison of Emedastine Difumarate 0.05% and Levocabastine Hydrochloride 0.05%: Reducing Chemosis and Eyelid Swelling in Subjects with Seasonal Allergic ConjunctivitisActa Ophthalmologica Scandinavica, 78
F. Mah, L. Rosenwasser, W. Townsend, J. Greiner, G. Bensch (2007)
Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge*Current Medical Research and Opinion, 23
E. Cook, J. Stahl, N. Barney, F. Graziano (2002)
Mechanisms of antihistamines and mast cell stabilizers in ocular allergic inflammation.Current drug targets. Inflammation and allergy, 1 2
M. Abelson, A. Kaplan (2002)
A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model.Clinical therapeutics, 24 3
J. Greiner, Kimberly Edwards-Swanson, A. Ingerman (2011)
Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%Clinical Ophthalmology (Auckland, N.Z.), 5
S. Imagama, Y. Matsuyama, Y. Yukawa, N. Kawakami, M. Kamiya, T. Kanemura, N. Ishiguro, Ñ. Imagama, N. Matsuyama, N. Ishiguro (2010)
A MULTICENTRE STUDY
S. Ono, K. Lane (2011)
Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitisDrug Design, Development and Therapy, 5
H. Engelhardt, R. Smits, R. Leurs, E. Haaksma, I. Esch (2009)
A new generation of anti-histamines: Histamine H4 receptor antagonists on their way to the clinic.Current opinion in drug discovery & development, 12 5
R. Thurmond, E. Gelfand, P. Dunford (2008)
The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistaminesNature Reviews Drug Discovery, 7
T. Kida, A. Fujii, Osamu Sakai, M. Iemura, Ikuyo Atsumi, Tomoyuki Wada, H. Sakaki (2010)
Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.Experimental eye research, 91 1
J. Yanni, L. Weimer, R. Glaser, L. Lang, S. Robertson, J. Spellman (1993)
Effect of lodoxamide on in vitro and in vivo conjunctival immediate hypersensitivity responses in rats.International archives of allergy and immunology, 101 1
S. Scoper, G. Berdy, S. Lichtenstein, J. Rubin, M. Bloomenstein, Robert Prouty, Cullen Vogelson, Michael Edwards, C. Waycaster, T. Pasquine, R. Gross, S. Robertson (2007)
Perception and quality of life associated with the use of olopatadine 0.2% (Pataday™) in patients with active allergic conjunctivitisAdvances in Therapy, 24
M. Abelson, G. Yamamoto, M. Allansmith (1980)
Effects of ocular decongestants.Archives of ophthalmology, 98 5
A. Leonardi (2005)
Emerging drugs for ocular allergyExpert Opinion on Emerging Drugs, 10
E. Zampeli, R. Thurmond, E. Tiligada (2009)
The histamine H4 receptor antagonist JNJ7777120 induces increases in the histamine content of the rat conjunctivaInflammation Research, 58
Use of topical antihistamines in the treatment of allergic conjunctivitis has evolved over the past several decades as our knowledge of the nature of the underlying disease has progressed. Formulations for the eye typically employ H1-receptor antagonists with a dual action, both directly as competitors for histamine receptor occupancy and as mast cell–stabilizing agents. Many of these compounds also display activity against late-phase allergic symptoms. Of the newest available drugs, several have a prolonged duration of action allowing once-daily dosing. Future development is likely to focus on long-acting agents such as these and on drugs that can target additional histamine receptor subtypes.
Current Allergy and Asthma Reports – Springer Journals
Published: Mar 25, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.